Efficacy and safety of once‐weekly versus once‐daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta‐analysis
Pooled result · HbA1c reductionResult — go to the resultMD −0.13 % 95% CI −0.23 to −0.03Authors' conclusion
The once-weekly basal insulin analogues seem to be at least equally efficient in glycaemic management and safe compared to once-daily injections in people with T2DM. Phase 4 RCTs are expected to shed further light on the effectiveness and safety of once-weekly insulin therapy over the long term.
Study context
- Population
- Patients with T2D in randomized controlled trials (RCTs) of once-weekly basal insulin analogues; Medline, Cochrane Library and Google Scholar searched until June 30, 2023
- Participants
- 3,962 patients9 RCTs
- Comparison
- Once-weekly vs once-daily basal insulin analogues
- Outcome
- Glycaemic control (HbA1c reduction)
Methodological detailsrandom-effects meta-analysis, double-independent study selection, data extraction and quality assessment, All RCTs had low risk of bias (RoB2)
- Random-effects meta-analysis
- Double-independent study selection, data extraction and quality assessment
- All RCTs had low risk of bias (RoB2)
Pooled result
HbA1c reduction
MD
−0.13 %
95% CI −0.23 to −0.03
P = 0.08
Once-weekly insulinsvs Once-daily insulin analogues
MD −0.13 % (95% CI −0.23 to −0.03); P = 0.08
As reported in the abstract
Further pooled results
| Outcome | MD (%) (95% CI) | P value | |
|---|---|---|---|
| Time in range | 3.54 (1.56–5.53) | P = 0.005 | |
| HbA1c reduction, subgroup icodecIcodecvs Once-daily insulinSubgroup analysis | −0.18 (−0.27 to −0.09) | P < 0.001 | |
| −50510Difference, % (linear scale) |
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| End-of-treatment HbA1c <6.5%, subgroup icodecIcodecvs Once-daily insulinSubgroup analysis | 1.75 (1.34–2.29) | P < 0.001 | |
| 0.512Odds ratio (log scale) |
Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Level 1 hypoglycaemia during the 24-hour period | 1.3 (1.04–1.64) | P = 0.02 | |
| Level 2 or 3 nocturnal hypoglycaemic events | 0.74 (0.56–0.97) | P = 0.03 | |
| 0.512Odds ratio (log scale) |
Serious adverse events
- No difference between the two groups
Original publication
Efficacy and safety of once‐weekly versus once‐daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 5 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →